NCAN

NCAN encodes neurocan, a brain-expressed chondroitin sulfate proteoglycan whose hyaluronan-binding domain directly engages hyaluronan to scaffold the brain extracellular matrix, including perineuronal nets and the interstitial matrix [PMID:9795216, PMID:bio_10.1101_2025.01.31.635882]. The isolated HA-binding domain is sufficient for this interaction: when secreted as a GFP fusion in mouse brain, it labels extracellular matrix in a manner that colocalizes with hyaluronan-binding protein and is abolished by hyaluronidase [PMID:bio_10.1101_2025.01.31.635882]. Neurocan is also expressed outside the nervous system, in human liver (PMID:24946282), and its expression rises in cortical and periventricular white matter during inflammatory CNS injury, coincident with reactive astrogliosis and neural progenitor proliferation, consistent with a role in lesion remodeling (PMID:21107918). Beyond hyaluronan engagement and these expression correlations, no downstream signaling mechanism or interaction partner has been characterized in the available corpus.

1. 1998 Medium

   Establishing the primary structure and tissue specificity of human neurocan was the first step in defining it as a discrete brain proteoglycan rather than an ortholog inferred from rodents.

   Evidence cDNA sequencing, Northern blot, and chromosomal mapping of the human NCAN/CSPG3 gene

   PMID:9795216

   Open questions at the time

   • no functional domain mapped at this stage
   • binding partners and matrix role not yet addressed
   • post-translational chondroitin sulfate modification not characterized
2. 2010 Low

   Linking neurocan expression to CNS inflammatory injury raised the question of whether it participates in lesion remodeling and progenitor responses.

   Evidence immunofluorescence and BrdU labeling in the EAE mouse model showing CSPG3 upregulation coincident with astrogliosis and NPC proliferation

   PMID:21107918

   Open questions at the time

   • correlative localization without functional rescue or loss-of-function
   • no mechanistic placement of NCAN in any signaling pathway
   • causal contribution to progenitor proliferation not tested
3. 2014 Low

   Detection of NCAN in human liver extended its expression beyond neural tissue, opening the question of an extra-neural function.

   Evidence RT-PCR and immunofluorescence on human liver tissue

   PMID:24946282

   Open questions at the time

   • localization only, no functional consequence established
   • hepatic interaction partners unknown
   • relevance to metabolic phenotypes not tested
4. 2025 Medium

   Direct demonstration that the HA-binding domain alone is sufficient to engage hyaluronan and label brain ECM established the molecular basis of neurocan's matrix-scaffolding role.

   Evidence AAV-expressed NCAN HA-binding domain–GFP fusion in mouse brain slices and cortex, validated by HABP colocalization and hyaluronidase sensitivity (preprint)

   PMID:bio_10.1101_2025.01.31.635882

   Open questions at the time

   • demonstrates a probe activity but not the full-length protein's in situ function
   • does not identify additional matrix or cell-surface partners
   • does not connect HA binding to perineuronal net assembly mechanism

• How NCAN coding and regulatory variation alters protein function to influence psychiatric and metabolic phenotypes remains unresolved by direct experiment.
• no variant-to-function experiment in the corpus
• downstream signaling pathway undefined
• interaction partners beyond hyaluronan unidentified